;PMID: 40703
;source_file_968.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..44] = [t:0..44]
;1)sentence:[e:50..156] = [t:50..156]
;2)section:[e:160..179] = [t:160..179]
;3)sentence:[e:183..362] = [t:183..362]
;4)sentence:[e:363..628] = [t:363..628]
;5)sentence:[e:629..773] = [t:629..773]
;6)sentence:[e:774..1054] = [t:774..1054]
;7)section:[e:1058..1100] = [t:1058..1100]

;section 0 Span:0..44
;Chem Biol Interact. 1979 Oct;27(2-3):163-75.
(SEC
  (FRAG (NNP:[0..4] Chem) (NNP:[5..9] Biol) (NNP:[10..18] Interact)
        (.:[18..19] .) (CD:[20..24] 1979) (HYPH:[25..32] Oct;27-LRB-)
        (CD:[32..33] 2) (HYPH:[33..34] -) (CD:[34..35] 3) (-RRB-:[35..36] -RRB-)
        (CD:[36..40] :163) (HYPH:[40..41] -) (CD:[41..43] 75) (.:[43..44] .)))

;sentence 1 Span:50..156
;The interaction of aliphatic analogs of methylene-dioxyphenyl compounds with 
;cytochromes P-450 and P-420.
;[69..86]:substance:"aliphatic analogs"
;[90..121]:substance:"methylene-dioxyphenyl compounds"
;[128..145]:cyp450:"cytochromes P-450"
;[128..139]...[150..155]:cyp450:"cytochromes"..."P-420"
(SENT
  (NP-HLN
    (NP (DT:[50..53] The) (NN:[54..65] interaction))
    (PP (IN:[66..68] of)
      (NP
        (NP (JJ:[69..78] aliphatic) (NNS:[79..86] analogs))
        (PP (IN:[87..89] of)
          (NP
            (NML (NN:[90..99] methylene) (HYPH:[99..100] -)
                 (NN:[100..111] dioxyphenyl))
            (NNS:[112..121] compounds)))))
    (PP (IN:[122..126] with)
      (NP
        (NP
          (NML-1 (NNS:[128..139] cytochromes))
          (NN:[140..145] P-450))
        (CC:[146..149] and)
        (NP
          (NML-1 (-NONE-:[149..149] *P*))
          (NN:[150..155] P-420))))
    (.:[155..156] .)))

;section 2 Span:160..179
;Dahl AR, Hodgson E.
(SEC
  (FRAG (NNP:[160..164] Dahl) (NNP:[165..167] AR) (,:[167..168] ,)
        (NNP:[169..176] Hodgson) (NNP:[177..179] E.)))

;sentence 3 Span:183..362
;The spectra resulting from the interaction of a series of substituted
;dioxolanes  with microsomal cytochromes P-450 or P-420, as well as purified
;cytochrome  P-450, were measured.
;[253..263]:substance:"dioxolanes"
;[281..298]:cyp450:"cytochromes P-450"
;[281..292]...[302..307]:cyp450:"cytochromes"..."P-420"
;[329..346]:cyp450:"cytochrome  P-450"
(SENT
  (S
    (NP-SBJ-3
      (NP (DT:[183..186] The) (NNS:[187..194] spectra))
      (VP (VBG:[195..204] resulting)
        (PP-CLR (IN:[205..209] from)
          (NP
            (NP (DT:[210..213] the) (NN:[214..225] interaction))
            (PP (IN:[226..228] of)
              (NP
                (NP (DT:[229..230] a) (NN:[231..237] series))
                (PP (IN:[238..240] of)
                  (NP (VBN:[241..252] substituted) (NNS:[253..263] dioxolanes)))))
            (PP (IN:[265..269] with)
              (NP
                (NP
                  (NP
                    (ADJP-2 (JJ:[270..280] microsomal))
                    
                    (NML-1 (NNS:[281..292] cytochromes))
                    (NN:[293..298] P-450))
                  (CC:[299..301] or)
                  (NP
                    (ADJP-2 (-NONE-:[301..301] *P*))
                    (NML-1 (-NONE-:[301..301] *P*))
                    (NN:[302..307] P-420)))
                (,:[307..308] ,)
                (CONJP (RB:[309..311] as) (RB:[312..316] well)
                       (IN:[317..319] as))
                (NP (VBN:[320..328] purified)
                   (NN:[329..339] cytochrome) (NN:[341..346] P-450))))))))
    (,:[346..347] ,)
    (VP (VBD:[348..352] were)
      (VP (VBN:[353..361] measured)
        (NP-3 (-NONE-:[361..361] *))))
    (.:[361..362] .)))

;sentence 4 Span:363..628
;With the exception of dioxolane, 4-methyldioxolane and  4-ethyldioxolane,
;these compounds interacted with ferric cytochrome P-450 to  give complexes
;exhibiting type I optical difference spectra, and, after  incubation with
;NADPH, spectra with peaks at about 430 nm.
;[385..394]:substance:"dioxolane"
;[396..413]:substance:"4-methyldioxolane"
;[419..435]:substance:"4-ethyldioxolane"
;[443..452]:substance:"compounds"
;[469..492]:cyp450:"ferric cytochrome P-450"
;[502..511]:substance:"complexes"
;[586..591]:substance:"NADPH"
;[615..624]:quantitative-value:"about 430"
;[625..627]:quantitative-units:"nm"
(SENT
  (S
    (PP (IN:[363..367] With)
      (NP
        (NP (DT:[368..371] the) (NN:[372..381] exception))
        (PP (IN:[382..384] of)
          (NP (NN:[385..394] dioxolane) (,:[394..395] ,)
              (NN:[396..413] 4-methyldioxolane) (CC:[414..417] and)
              (NN:[419..435] 4-ethyldioxolane)))))
    (,:[435..436] ,)
    (NP-SBJ-1 (DT:[437..442] these) (NNS:[443..452] compounds))
    (VP (VBD:[453..463] interacted)
      (PP-CLR (IN:[464..468] with)
        (NP (JJ:[469..475] ferric) (NN:[476..486] cytochrome)
            (NN:[487..492] P-450)))
      (S-ADV
        (NP-SBJ-1 (-NONE-:[492..492] *))
        (VP (TO:[493..495] to)
          (VP (VB:[497..501] give)
            (NP
              (NP
                (NP (NNS:[502..511] complexes))
                (VP (VBG:[512..522] exhibiting)
                  (NP
                    (NML (NN:[523..527] type) (CD:[528..529] I))
                    (JJ:[530..537] optical) (NN:[538..548] difference)
                     (NNS:[549..556] spectra))))
              (,:[556..557] ,) (CC:[558..561] and) (,:[561..562] ,)
              (NP
                (PP-TMP (IN:[563..568] after)
                  (NP
                    (NP (NN:[570..580] incubation))
                    (PP (IN:[581..585] with)
                      (NP (NN:[586..591] NADPH)))))
                (,:[591..592] ,)
                (NP (NNS:[593..600] spectra))
                (PP (IN:[601..605] with)
                  (NP
                    (NP (NNS:[606..611] peaks))
                    (PP (IN:[612..614] at)
                      (NP
                        (QP (RB:[615..620] about) (CD:[621..624] 430))
                        (NN:[625..627] nm)))))))))))
    (.:[627..628] .)))

;sentence 5 Span:629..773
;These complexes, as  well as those formed from dioxolanes in the presence of
;cumene hydroperoxide,  inhibit the binding of CO to the cytochrome.
;[635..644]:substance:"complexes"
;[676..686]:substance:"dioxolanes"
;[706..726]:substance:"cumene hydroperoxide"
;[752..754]:substance:"CO"
;[762..772]:substance:"cytochrome"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[629..634] These) (NNS:[635..644] complexes))
      (,:[644..645] ,)
      (CONJP (RB:[646..648] as) (RB:[650..654] well) (IN:[655..657] as))
      (NP
        (NP (DT:[658..663] those))
        (VP (VBN:[664..670] formed)
          (NP (-NONE-:[670..670] *))
          (PP (IN:[671..675] from)
            (NP
              (NP (NNS:[676..686] dioxolanes))
              (PP (IN:[687..689] in)
                (NP
                  (NP (DT:[690..693] the) (NN:[694..702] presence))
                  (PP (IN:[703..705] of)
                    (NP (NN:[706..712] cumene) (NN:[713..726] hydroperoxide))))))))))
    (,:[726..727] ,)
    (VP (VBP:[729..736] inhibit)
      (NP
        (NP (DT:[737..740] the) (NN:[741..748] binding))
        (PP (IN:[749..751] of)
          (NP (NN:[752..754] CO)))
        (PP (TO:[755..757] to)
          (NP (DT:[758..761] the) (NN:[762..772] cytochrome)))))
    (.:[772..773] .)))

;sentence 6 Span:774..1054
;Consideration of the known  chemistry of dioxolanes, together with recent
;advances in the understanding of  double Soret spectra, lead to a possible
;explanation for the differences between  the spectra of dioxolanes and their
;aromatic analogs, the methylenedioxyphenyl  compounds.
;[815..825]:substance:"dioxolanes"
;[979..989]:substance:"dioxolanes"
;[1000..1016]:substance:"aromatic analogs"
;[1022..1053]:substance:"methylenedioxyphenyl  compounds"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[774..787] Consideration))
      (PP (IN:[788..790] of)
        (NP
          (NP (DT:[791..794] the) (VBN:[795..800] known)
              (NN:[802..811] chemistry))
          (PP (IN:[812..814] of)
            (NP (NNS:[815..825] dioxolanes))))))
    (,:[825..826] ,)
    (ADVP (RB:[827..835] together)
      (PP (IN:[836..840] with)
        (NP
          (NP (JJ:[841..847] recent) (NNS:[848..856] advances))
          (PP (IN:[857..859] in)
            (NP
              (NP (DT:[860..863] the) (NN:[864..877] understanding))
              (PP (IN:[878..880] of)
                (NP (JJ:[882..888] double) (NNP:[889..894] Soret)
                    (NNS:[895..902] spectra))))))))
    (,:[902..903] ,)
    (VP (VBP:[904..908] lead)
      (PP-CLR (TO:[909..911] to)
        (NP
          (NP (DT:[912..913] a) (JJ:[914..922] possible)
              (NN:[923..934] explanation))
          (PP (IN:[935..938] for)
            (NP
              (NP (DT:[939..942] the) (NNS:[943..954] differences))
              (PP (IN:[955..962] between)
                (NP
                  (NP (DT:[964..967] the) (NNS:[968..975] spectra))
                  (PP (IN:[976..978] of)
                    (NP
                      (NP (NNS:[979..989] dioxolanes))
                      (CC:[990..993] and)
                      (NP
                        (NP (PRP$:[994..999] their)
                           (JJ:[1000..1008] aromatic) (NNS:[1009..1016] analogs))
                        (,:[1016..1017] ,)
                        (NP (DT:[1018..1021] the)
                           (NN:[1022..1042] methylenedioxyphenyl)
                           (NNS:[1044..1053] compounds))))))))))))
    (.:[1053..1054] .)))

;section 7 Span:1058..1100
;PMID: 40703 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1058..1062] PMID) (::[1062..1063] :) (CD:[1064..1069] 40703)
        (IN:[1070..1071] -LSB-) (NNP:[1071..1077] PubMed) (HYPH:[1078..1079] -)
        (JJ:[1080..1087] indexed) (IN:[1088..1091] for)
        (NNP:[1092..1100] MEDLINE-RSB-)))
